Toxicological Sciences 68, 249-264 (2002)
Copyright © 2002 by the Society of Toxicology
SAFETY EVALUATION |
Subchronic Toxicity Studies on Perfluorooctanesulfonate Potassium Salt in Cynomolgus Monkeys
* 3M Medical Department, Saint Paul, Minnesota 55133;
Covance, Madison, Wisconsin 53704; and
3M Environmental Laboratory, Saint Paul, Minnesota 55133
This study was conducted to determine the earliest measurable response of primates to low-level perfluorooctanesulfonate (PFOS) exposure and to provide information to reduce uncertainty in human health risk assessment. Groups of male and female monkeys received 0, 0.03, 0.15, or 0.75 mg/kg/day potassium PFOS orally for 182 days. Recovery animals from each group, except the 0.03 mg/kg/day dose group, were monitored for one year after treatment. Significant adverse effects occurred only in the 0.75 mg/kg/day dose group and included compound-related mortality in 2 of 6 male monkeys, decreased body weights, increased liver weights, lowered serum total cholesterol, lowered triiodothyronine concentrations (without evidence of hypothyroidism), and lowered estradiol levels. Decreased serum total cholesterol occurred in the 0.75 mg/kg/day dose group at serum PFOS levels > 100 ppm. Hepatocellular hypertrophy and lipid vacuolation were present at term in the 0.75 mg/kg/day dose group. No peroxisomal (palmitoyl CoA oxidase) or cell proliferation (proliferating cell nuclear antigen immunohistochemistry) was detected. Complete reversal of clinical and hepatic effects and significant decreases in serum and liver PFOS occurred within 211 days posttreatment. Liver-to-serum PFOS ratios were comparable in all dose groups, with a range of 1:1 to 2:1. Serum concentrations associated with no adverse effects (0.15 mg/kg/day) were 82.6 ± 25.2 ppm for males and 66.8 ± 10.8 ppm for females. Comparison of serum PFOS concentrations associated with no adverse effect in this study to those reported in human blood samples (0.028 ± 0.014 ppm) indicated an adequate margin of safety.
Key Words: perfluorooctanesulfonate; cholesterol; hypolipidemia; peroxisomes; hepatotoxicity; electron microscopy; primate.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. M. Peden-Adams, J. M. Keller, J. G. EuDaly, J. Berger, G. S. Gilkeson, and D. E. Keil Suppression of Humoral Immunity in Mice following Exposure to Perfluorooctane Sulfonate Toxicol. Sci., July 1, 2008; 104(1): 144 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Keil, T. Mehlmann, L. Butterworth, and M. M. Peden-Adams Gestational Exposure to Perfluorooctane Sulfonate Suppresses Immune Function in B6C3F1 Mice Toxicol. Sci., May 1, 2008; 103(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lau, K. Anitole, C. Hodes, D. Lai, A. Pfahles-Hutchens, and J. Seed Perfluoroalkyl Acids: A Review of Monitoring and Toxicological Findings Toxicol. Sci., October 1, 2007; 99(2): 366 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Wolf, S. E. Fenton, J. E. Schmid, A. M. Calafat, Z. Kuklenyik, X. A. Bryant, J. Thibodeaux, K. P. Das, S. S. White, C. S. Lau, et al. Developmental Toxicity of Perfluorooctanoic Acid in the CD-1 Mouse after Cross-Foster and Restricted Gestational Exposures Toxicol. Sci., February 1, 2007; 95(2): 462 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. O'Brien and K. B. Wallace Mitochondrial Permeability Transition as the Critical Target of N-Acetyl Perfluorooctane Sulfonamide Toxicity in Vitro Toxicol. Sci., November 1, 2004; 82(1): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Shipley, C. H. Hurst, S. S. Tanaka, F. L. DeRoos, J. L. Butenhoff, A. M. Seacat, and D. J. Waxman trans-Activation of PPAR{alpha} and Induction of PPAR{alpha} Target Genes by Perfluorooctane-Based Chemicals Toxicol. Sci., July 1, 2004; 80(1): 151 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B H Alexander, G W Olsen, J M Burris, J H Mandel, and J S Mandel Mortality of employees of a perfluorooctanesulphonyl fluoride manufacturing facility Occup. Environ. Med., October 1, 2003; 60(10): 722 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Lau, J. R. Thibodeaux, R. G. Hanson, J. M. Rogers, B. E. Grey, M. E. Stanton, J. L. Butenhoff, and L. A. Stevenson Exposure to Perfluorooctane Sulfonate during Pregnancy in Rat and Mouse. II: Postnatal Evaluation Toxicol. Sci., August 1, 2003; 74(2): 382 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Thibodeaux, R. G. Hanson, J. M. Rogers, B. E. Grey, B. D. Barbee, J. H. Richards, J. L. Butenhoff, L. A. Stevenson, and C. Lau Exposure to Perfluorooctane Sulfonate during Pregnancy in Rat and Mouse. I: Maternal and Prenatal Evaluations Toxicol. Sci., August 1, 2003; 74(2): 369 - 381. [Abstract] [Full Text] [PDF]
|
|